Craig-Hallum Starts Design Therapeutics Inc (DSGN) at Buy Dec 3, 2025 09:04AM
Leerink Partners Upgrades Design Therapeutics Inc (DSGN) to Outperform Dec 3, 2025 06:39AM
RBC Capital Upgrades Design Therapeutics Inc (DSGN) to Outperform Nov 20, 2025 05:05AM
Design Therapeutics plans DM1 patient dosing for first half 2026 Nov 5, 2025 04:03PM
RBC Capital Reiterates Sector Perform Rating on Design Therapeutics Inc (DSGN) Jun 4, 2025 08:10AM


Jun 4, 2025 07:02AM Design Therapeutics Inc. (DSGN) Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
May 7, 2025 06:01PM Design Therapeutics, Inc. (DSGN) Misses Q1 EPS by 2c
May 1, 2025 08:04AM Design Therapeutics Inc. (DSGN) Announces Favorable Phase 1 Data for DT-168
Apr 17, 2025 08:01AM Design Therapeutics (DSGN) Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
Mar 10, 2025 07:08AM Design Therapeutics, Inc. (DSGN) Tops Q4 EPS by 2c
Nov 8, 2024 04:28PM Design Therapeutics, Inc. (DSGN) Tops Q3 EPS by 1c
Aug 5, 2024 03:59PM Design Therapeutics, Inc. (DSGN) Tops Q2 EPS by 2c